manifesto

• The next generation of health-enabling companies won't be pharmas; they'll be consumer-facing precision medicine cos.
• We can see already a trend of diseases, mechanisms, and modalities becoming more complex and personalized. To deal with this, we need systems capable of predicting (and orchestrating) responders to complex clinical outcomes. I spend most of my time now working on reasoning models to do this, using biotech markets as a feedback loop.
• Finally, we need an axis to reprogram human health in a closed loop—likely via HSCs. I engineered a compound (from my dorm room with foundation models I built in high school) that restores cell resilience and is being developed as a best-in-class medium for the logistical layer of autologous cell banking/therapy.